Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders

Overview

Journal Brain Sci

Publisher MDPI

Date 2022 May 28

PMID 35624975

Authors

Maria Flores-Lopez

Nuria Garcia-Marchena

Pedro Araos

Nerea Requena-Ocana

Oscar Porras-Perales

Sandra Torres-Galvan

Juan Suarez

Nieves Pizarro

Rafael de la Torre

Gabriel Rubio

Juan Jesus Ruiz-Ruiz

Fernando Rodriguez de Fonseca

Antonia Serrano

Francisco Javier Pavon-Moron

Affiliations

Soon will be listed here.

Abstract

Preclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in drug addiction. Recently, we reported alterations in the plasma concentrations of LPA species in patients with alcohol use disorder (AUD). As there are sex differences in drug addiction, the main aim of the present study was to investigate whether relevant LPA species (16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA) were associated with sex and/or substance use disorder (SUD). This exploratory study was conducted in 214 abstinent patients with lifetime SUD, and 91 healthy control subjects. The SUD group was divided according to the diagnosis of AUD and/or cocaine use disorder (CUD). Participants were clinically assessed, and plasma samples were collected to determine LPA species and total LPA. We found that LPA concentrations were significantly affected by sex, and women showed higher concentrations than men. In addition, there were significantly lower 16:0-LPA, 18:2-LPA and total LPA concentrations in patients with SUD than in controls. Namely, patients with CUD and AUD + CUD showed lower LPA concentrations than controls or patients with AUD. In conclusion, our data suggest that LPA species could be potential biomarkers for SUD in women and men, which could contribute to a better stratification of these patients in treatment programs.

Citing Articles

Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder.

Requena-Ocana N, Flores-Lopez M, Garcia-Marchena N, Pavon-Moron F, Pedraza C, Wallace A Int J Mol Sci. 2023; 24(21).

PMID: 37958570 PMC: 10649657. DOI: 10.3390/ijms242115586.

Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders.

Flores-Lopez M, Garcia-Marchena N, Pavon-Moron F, Requena-Ocana N, Sanchez-Marin L, Martin-Chaves L Transl Psychiatry. 2023; 13(1):215.

PMID: 37344453 PMC: 10284796. DOI: 10.1038/s41398-023-02523-1.

Sexual Differences in Addictions and Dual Disorders: Importance of Gender Perspective.

Benito A, Rodriguez de Fonseca F, Haro G Brain Sci. 2022; 12(10).

PMID: 36291280 PMC: 9599507. DOI: 10.3390/brainsci12101346.

References

Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J . Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007; 41(6):616-23. DOI: 10.1097/01.mcg.0000225642.90898.0e. View

Flores-Lopez M, Garcia-Marchena N, Pavon F, Lara E, Porras-Perales O, Araos P . Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease. Biomedicines. 2021; 9(9). PMC: 8469650. DOI: 10.3390/biomedicines9091207. View

Flores-Bonilla A, Richardson H . Sex Differences in the Neurobiology of Alcohol Use Disorder. Alcohol Res. 2020; 40(2):04. PMC: 7532022. DOI: 10.35946/arcr.v40.2.04. View

Grella C . From generic to gender-responsive treatment: changes in social policies, treatment services, and outcomes of women in substance abuse treatment. J Psychoactive Drugs. 2009; Suppl 5:327-43. DOI: 10.1080/02791072.2008.10400661. View

Garcia-Marchena N, Pizarro N, Pavon F, Martinez-Huelamo M, Flores-Lopez M, Requena-Ocana N . Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients. Sci Rep. 2020; 10(1):17163. PMC: 7555527. DOI: 10.1038/s41598-020-74155-0. View

Castilla-Ortega E, Pavon F, Sanchez-Marin L, Estivill-Torrus G, Pedraza C, Blanco E . Both genetic deletion and pharmacological blockade of lysophosphatidic acid LPA1 receptor results in increased alcohol consumption. Neuropharmacology. 2015; 103:92-103. DOI: 10.1016/j.neuropharm.2015.12.010. View

ROBINS L, Wing J, Wittchen H, Helzer J, Babor T, Burke J . The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988; 45(12):1069-77. DOI: 10.1001/archpsyc.1988.01800360017003. View

Chen J, Li H, Xu W, Guo X . Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer. BMC Gastroenterol. 2021; 21(1):58. PMC: 7877052. DOI: 10.1186/s12876-021-01635-6. View

Baker D, Desiderio D, Miller D, Tolley B, Tigyi G . Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem. 2001; 292(2):287-95. DOI: 10.1006/abio.2001.5063. View

10.

Harp S, Martini M, Lynch W, Rissman E . Sexual Differentiation and Substance Use: A Mini-Review. Endocrinology. 2020; 161(9). PMC: 7438703. DOI: 10.1210/endocr/bqaa129. View

11.

Zhang X, Li M, Yin N, Zhang J . The Expression Regulation and Biological Function of Autotaxin. Cells. 2021; 10(4). PMC: 8073485. DOI: 10.3390/cells10040939. View

12.

Kurano M, Suzuki A, Inoue A, Tokuhara Y, Kano K, Matsumoto H . Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic acid in acute coronary syndrome. Arterioscler Thromb Vasc Biol. 2014; 35(2):463-70. DOI: 10.1161/ATVBAHA.114.304748. View

13.

Ait-Daoud N, Blevins D, Khanna S, Sharma S, Holstege C, Amin P . Women and Addiction: An Update. Med Clin North Am. 2019; 103(4):699-711. DOI: 10.1016/j.mcna.2019.03.002. View

14.

Yung Y, Stoddard N, Mirendil H, Chun J . Lysophosphatidic Acid signaling in the nervous system. Neuron. 2015; 85(4):669-82. PMC: 4400838. DOI: 10.1016/j.neuron.2015.01.009. View

15.

Orio L, Pavon F, Blanco E, Serrano A, Araos P, Pedraz M . Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid. Curr Pharm Des. 2013; 19(40):7036-49. DOI: 10.2174/138161281940131209143421. View

16.

Choi J, Chun J . Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta. 2012; 1831(1):20-32. PMC: 3693945. DOI: 10.1016/j.bbalip.2012.07.015. View

17.

Baker D, Umstot E, Desiderio D, Tigyi G . Quantitative analysis of lysophosphatidic acid in human blood fractions. Ann N Y Acad Sci. 2000; 905:267-9. DOI: 10.1111/j.1749-6632.2000.tb06557.x. View

18.

Blanco E, Bilbao A, Luque-Rojas M, Palomino A, Bermudez-Silva F, Suarez J . Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors. Psychopharmacology (Berl). 2011; 220(1):27-42. DOI: 10.1007/s00213-011-2446-6. View

19.

Michalczyk A, Budkowska M, Dolegowska B, Chlubek D, Safranow K . Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters. Lipids Health Dis. 2017; 16(1):140. PMC: 5521143. DOI: 10.1186/s12944-017-0536-0. View

20.

Riaz A, Huang Y, Johansson S . G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling. Int J Mol Sci. 2016; 17(2):215. PMC: 4783947. DOI: 10.3390/ijms17020215. View